Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:571609.
doi: 10.1155/2014/571609. Epub 2014 Dec 4.

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

Nusrat Homaira  1 , William Rawlinson  2 , Thomas L Snelling  3 , Adam Jaffe  1
Affiliations
Review

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective

Nusrat Homaira et al. Int J Pediatr. 2014.

Abstract

Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV-associated respiratory illness. This recommendation is based on evidence of efficacy when used under clinical trial conditions. However the real-world effectiveness of palivizumab outside of clinical trials among different patient populations is not well established. We performed a systematic review focusing on postlicensure observational studies of the protective effect of palivizumab prophylaxis for reducing RSV-associated hospitalizations in infants and children at high risk of severe infection. We searched studies published in English between 1 January 1999 and August 2013 and identified 420 articles, of which 20 met the inclusion criteria. This review supports the recommended use of palivizumab for reducing RSV-associated hospitalization rates in premature infants born at gestational age < 33 weeks and in children with chronic lung and heart diseases. Data are limited to allow commenting on the protective effect of palivizumab among other high risk children, including those with Down syndrome, cystic fibrosis, and haematological malignancy, indicating further research is warranted in these groups.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram for selection of papers for the review.
Figure 2
Figure 2
Characteristics of the selected studies on effectiveness of palivizumab in reducing RSV-associated hospitalization in high risk infants and children.
See this image and copyright information in PMC

References

    1. Nair H., Nokes D. J., Gessner B. D., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet. 2010;375(9725):1545–1555. doi: 10.1016/S0140-6736(10)60206-1. - DOI - PMC - PubMed
    1. Madhi S. A., Kuwanda L., Cutland C., Klugman K. P. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. Journal of Clinical Virology. 2006;36(3):215–221. doi: 10.1016/j.jcv.2006.03.010. - DOI - PubMed
    1. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3, part 1):531–537. doi: 10.1542/peds.102.3.531. - DOI - PubMed
    1. Simoes E. A. F. Respiratory syncytial virus infection. The Lancet. 1999;354(9181):847–852. doi: 10.1016/S0140-6736(99)80040-3. - DOI - PubMed
    1. Stevens T. P., Sinkin R. A., Hall C. B., Maniscalco W. M., McConnochie K. M. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Archives of Pediatrics and Adolescent Medicine. 2000;154(1):55–61. - PubMed